AERIのチャート
AERIの企業情報
| symbol | AERI |
|---|---|
| 会社名 | Aerie Pharmaceuticals Inc （アエリ―・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アエリー･ファーマシューティカル(Aerie Pharmaceuticals Inc.)は臨床病期の製薬会社である。同社は緑内障及び眼の他の疾患の患者のための治療法の発見・開発・商業化に従事する。同社の製品候補には、Rhopressa（netarsudil点眼液）0.02％（Rhopressa）、Roclatan（netarsudil /ラタノプロスト点眼液）0.02％/ 0.005％（Roclatan）が含まれる。同社の製品候補は、開放隅角緑内障および高眼圧症患者の眼内圧（IOP）を下げるように設計される。そのRhopressaは1日1回の点眼薬である。Rhopressaは、IOPを低下させる生化学的標的であるRhoキナーゼ（ROCK）およびノルエピネフリントランスポーター（NET）を阻害する。そのRoclatanは、オープンアングルの緑内障患者の治療薬として処方されているRhopressaとlatanoprostの1日1回、固定用量の組み合わせである。同社はRoclatanの第III相臨床試験を実施している。 アエリ―・ファ―マシュ―ティカルズは米国の製薬会社。緑内障とその他目の疾患治療薬の発見、開発、商業化を行う。緑内障と高眼圧症向けに一日一回投薬で眼圧を下げるRhoキナ―ゼ阻害剤「ロ―プレッサ」と「ロクラタン」の第3相治験を行う。また、第2世代のRhoキナ―ゼ阻害剤が臨床前段階。本社はカリフォルニア州。 Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC. |
| 本社所在地 | 4301 Emperor Boulevard Suite 400 Durham CA 27703 USA |
| 代表者氏名 | Vicente Anido ヴィセンテ・アニード |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 919-313-9650 |
| 設立年月日 | 38504 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 160人 |
| url | www.aeriepharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aeri |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -187.08400 |
| 終値（lastsale） | 54.17 |
| 時価総額（marketcap） | 2449689445.01 |
| 時価総額 | 時価総額（百万ドル） 2406.276 |
| 売上高 | 売上高（百万ドル） 2.42300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2244.172 |
| 当期純利益 | 当期純利益（百万ドル） -186.60800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aerie Pharmaceuticals Inc revenues increased from $0K to $2.4M. Net loss increased 77% to $95.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative -Other increase from $22.6M to $53.3M (expense) Research and development - Other increase of 39% to $26.5M (expense). |
AERIのテクニカル分析
AERIのニュース
Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update 2020/08/06 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a general business update. “Our second quarter results highlight the continued demand for both products in ou
Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020 2020/07/30 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its second quarter 2020 financial results will be released after the market closes on Thursday, August 6, 2020. Following the release, the Company will host a live conference ca
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors 2020/06/11 10:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today announced that Peter J. McDonnell, M.D., has been appointed to the Company’s Board of Directors and will also be a member of both the Nominating and Corporate Governance
Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue? 2020/06/05 15:31:59 Zacks Investment Research
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update 2020/05/06 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company op
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors 2020/06/11 10:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today announced that Peter J. McDonnell, M.D., has been appointed to the Company’s Board of Directors and will also be a member of both the Nominating and Corporate Governance
Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue? 2020/06/05 15:31:59 Zacks Investment Research
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update 2020/05/06 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company op
Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference 2020/05/05 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2020 Healthcare Conference on
Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 2020/04/29 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live confer
Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update 2020/05/06 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company op
Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference 2020/05/05 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2020 Healthcare Conference on
Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 2020/04/29 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live confer